RT Journal Article
SR Electronic
T1 Modifiable and non-modifiable risk factors for COVID-19: results from UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.28.20083295
DO 10.1101/2020.04.28.20083295
A1 Ho, Frederick K
A1 Celis-Morales, Carlos A
A1 Gray, Stuart R
A1 Katikireddi, S Vittal
A1 Niedzwiedz, Claire L
A1 Hastie, Claire
A1 Lyall, Donald M
A1 Ferguson, Lyn D
A1 Berry, Colin
A1 Mackay, Daniel F
A1 Gill, Jason MR
A1 Pell, Jill P
A1 Sattar, Naveed
A1 Welsh, Paul
YR 2020
UL http://medrxiv.org/content/early/2020/05/02/2020.04.28.20083295.abstract
AB Background Information on risk factors for COVID-19 is sub-optimal. We investigated demographic, lifestyle, socioeconomic, and clinical risk factors, and compared them to risk factors for pneumonia and influenza in UK Biobank.Methods UK Biobank recruited 37–70 year olds in 2006–2010 from the general population. The outcome of confirmed COVID-19 infection (positive SARS-CoV-2 test) was linked to baseline UK Biobank data. Incident influenza and pneumonia were obtained from primary care data. Poisson regression was used to study the association of exposure variables with outcomes.Findings Among 428,225 participants, 340 had confirmed COVID-19. After multivariable adjustment, modifiable risk factors were higher body mass index (RR 1.24 per SD increase), smoking (RR 1.38), slow walking pace as a proxy for physical fitness (RR 1.66) and use of blood pressure medications as a proxy for hypertension (RR 1.40). Non-modifiable risk factors included older age (RR 1.10 per 5 years), male sex (RR 1.64), black ethnicity (RR 1.86), socioeconomic deprivation (RR 1.26 per SD increase in Townsend Index), longstanding illness (RR 1.38) and high cystatin C (RR 1.24 per 1 SD increase). The risk factors overlapped with pneumonia somewhat; less so for influenza. The associations with modifiable risk factors were generally stronger for COVID-19, than pneumonia or influenza.Interpretation These findings suggest that modification of lifestyle may help to reduce the risk of COVID-19 and could be a useful adjunct to other interventions, such as social distancing and shielding of high risk.Funding British Heart Foundation, Medical Research Council, Chief Scientist Office.Competing Interest StatementJPP is a member of the UK Biobank Steering Committee. Apart from the funding acknowledged below, we declare no other competing interests.Funding StatementThe work in this study is supported by the British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217. CLN acknowledges funding from a Medical Research Council Fellowship (MR/R024774/1). SVK acknowledge funding from the Medical Research Council (MC_UU_12017/13) and Scottish Government Chief Scientist Office (SPHSU13). SVK also acknowledges funding from NRS Senior Clinical Fellowship (SCAF/15/02). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank data can be requested by bona fide researchers for approved projects, including replication, through https://www.ukbiobank.ac.uk/